newsletter

Subscribe to the newsletter

Subscribe to the newsletter

Product Highlights

Bi-Flow® ECMO – The unique bidirectional cannula is now validated up to 29 days

April 2020

After a successful first year of experience in the cardiac surgery setting, Bi-Flow is now validated for up to 29 days of use. This unique bidirectional cannula is designed to reduce the risk of limb ischemia in an easy, safe and reproducible way for patients receiving ECMO.

read more

digest

November 2019

read more

July 2019

read more

multimedia

Videos

This video animation focuses on Bi-Flow unique features to provide stable distal perfusion to the lower limb without compromising systemic flow to the patient.

video archive

Bi-Flow Arterial Cannulae Animation

play video

resources

Product Brochures

Bi-Flow Arterial Cannulae

An overview of LivaNova’s breakthrough device designed to prevent leg ischemia. Read more

download

MICS Cannulae – Expanding performance standards

An Overview of our Comprehensive Line of MICS Cannulae. Read more

download

PureFlex™ Arterial Cannulae

The all new Arterial Cannulae family for conventional cardiac surgery. Read more

download

PureFlex Arterial Cannulae – US Version

The all new Arterial Cannulae family for conventional cardiac surgery. Read more

download

Clinical Leaflets

Bi-Flow Phase 1 Clinical study

Bi-Flow Arterial Cannula is safe and easy to insert and provides stable distal perfusion of the cannulated limb. Read more

download

Bi-Flow in Animal Model

Bi-Flow Arterial Cannulae demonstrate significantly higher blood flow in the lower extremity compared to conventional... Read more

download

Optiflow Arterial Cannulae demonstrate shear stress reduction

The Dr. Assmann paper demonstrate the significant wall shear stress reduction of Optiflow through a comparison with a... Read more

download

Optiflow Arterial Cannulae reduce pressure gradient

The article written by Dr. Scharfschwerdt measured and compared the pressure gradients and back pressure of... Read more

download